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Metformin, the world’s most prescribed anti-diabetic drug, is also effective in 31 
preventing Type 2 diabetes in people at high risk1,2. Over 60% of this effect is 32 
attributable to metformin’s ability to lower body weight in a sustained manner3. 33 
The molecular mechanisms through which metformin lowers body weight are 34 
unknown.  In two, independent randomised controlled clinical trials, circulating 35 
levels of GDF15, recently described to reduce food intake and lower body weight 36 
through a brain stem-restricted receptor, were increased by metformin.  In wild-37 
type mice, oral metformin increased circulating GDF15 with GDF15 expression 38 
increasing predominantly in the distal intestine and the kidney. Metformin 39 
prevented weight gain in response to high fat diet in wild-type mice but not in 40 
mice lacking GDF15 or its receptor GFRAL. In obese, high fat-fed mice, the 41 
effects of metformin to reduce body weight were reversed by a GFRAL 42 
antagonist antibody. Metformin had effects on both energy intake and energy 43 
expenditure that required GDF15. Metformin retained its ability to lower 44 
circulating glucose levels in the absence of GDF15 action. In summary, 45 
metformin elevates circulating levels of GDF15, which are necessary for its 46 
beneficial effects on energy balance and body weight, major contributors to its 47 
action as a chemopreventive agent. 48 
 49 
 50 
 51 
 52 
 53 
Metformin has been used as a treatment for Type 2 diabetes since the 1950s. Recent 54 
studies have shown that it can also prevent or delay the onset of Type 2 diabetes in 55 
people at high risk 1 2 . At-risk individuals treated with metformin manifest a reduction 56 
in body weight,  glucose and insulin levels and enhanced insulin sensitivity 3. Although 57 
many mechanisms for the insulin sensitizing actions of metformin have been proposed 58 
4, none would explain weight loss. The robustness and persistence metformin-induced 59 
weight loss in participants in the Diabetes Prevention Program (DPP) has drawn 60 
attention to the importance of this to the chemopreventive effects of the drug 5.  A 61 
recent observational epidemiological study6 noted a strong association of metformin 62 
use with circulating levels of GDF15, a peptide hormone produced by cells responding 63 
to stressors7 . GDF15 acts through a receptor complex solely expressed in the 64 
hindbrain, through which it suppress food intake 8-11. We hypothesized that 65 
metformin’s effects to lower body weight might involve the elevation of circulating 66 
levels of GDF15.  67 
Human studies 68 
We first measured circulating GDF15 in a short term human study12 and found that 69 
after 2 weeks of metformin,  there was  a  ~2.5-fold increase  in  mean circulating 70 
GDF15 (Fig. 1a).   71 
To determine if this increase was sustained, we measured circulating GDF15 levels at 72 
6, 12 and 18 months in all available participants in CAMERA 13, a randomized placebo-73 
control trial of metformin in people without diabetes but with a history of cardiovascular 74 
disease. In this study, metformin treated participants lost ~3.5% of body weight with 75 
no significant change in weight in the placebo arm13. Metformin treatment was 76 
associated with significantly (p < 0.0001) increased levels of circulating GDF15 at all 77 
three time points (Fig.1b and Extended Data Fig.1b,c,d,e). Furthermore, the change 78 
in serum GDF15 from baseline in metformin recipients was significantly correlated (r=-79 
0.26, p=0.024) with weight loss (Extended Data Fig. 1a). 80 
The correlation of GDF15 increment with changes in body weight, while statistically 81 
significant, was modest in size. While we consider it does contribute to weight loss in 82 
some individuals taking metformin, we acknowledge is by no means necessary and 83 
there are individuals with increases in GDF-15 that do not exhibit weight loss. 84 
However, in the context of a long term human study with imperfect drug compliance 85 
and intermittent sampling of GDF15 levels it is noteworthy that such an association 86 
was seen at all. Further, there was no association of weight change with change in 87 
GDF-15 in the placebo group (r=-0.0374, p=0.740, n=81).” 88 
Murine studies 89 
Following these findings in humans, we undertook a series of animal experiments to 90 
determine the potential causal link between the changes in GDF-15 and weight 91 
changes induced by metformin. We administered metformin to high fat diet fed mice 92 
by oral gavage and measured serum GDF15. A single dose of 300 mg/kg of metformin 93 
increased GDF15 levels for at least 8 hours (Fig. 1c). A higher dose of metformin, 600 94 
mg/kg, increased serum GDF15 levels 4-6 fold at 4 and 8-hours post-dose, which were 95 
sustained over vehicle-treated mice for 24 hours. The effects of metformin in chow-96 
fed mice were less pronounced (Extended Data Fig.2) suggesting an interaction 97 
between metformin and the high fat fed state.  98 
To determine the extent to which metformin- induced increase in GDF15 affects  body 99 
weight, Gdf15 +/+ and Gdf15 -/- mice were switched from chow to a high fat diet and  100 
dosed with metformin for 11 days. High fat feeding induced similar weight gain in both 101 
genotypes (Fig. 2a).  Metformin completely prevented weight gain in Gdf15 +/+ mice 102 
but Gdf15 -/- mice were insensitive to the weight-reducing effects of metformin (Fig.2a, 103 
Extended data Fig.3a). Metformin significantly reduced cumulative food intake in wild 104 
type mice but this effect was abolished in Gdf15-/- mice (Fig. 2b).   105 
 106 
The identical protocol was applied to mice lacking GFRAL, the ligand-binding 107 
component of the hindbrain-expressed GDF15 receptor complex.  Consistent with the 108 
results in mice lacking GDF15, metformin was unable to prevent weight gain in Gfral -109 
/- mice (Fig. 2c, Extended data Fig.3b), despite similar levels of serum GDF15 110 
(Extended Data Fig. 4a,b). In this experiment, the reduction in cumulative food intake 111 
did not reach statistical significance (Extended Data Fig. 4c). 112 
To investigate the contribution of GDF15/GFRAL signalling to sustained, metformin-113 
dependent weight regulation, we performed a 9-week study in which mice received 114 
approximately 250-300 mg/kg/day of metformin incorporated into their high-fat diet.  115 
The mice lost ~10% body weight after 1 month on this diet (Fig. 2d). At this time, an 116 
anti-GFRAL antagonist antibody or IgG control was administered. Metformin-117 
consuming mice treated with anti-GFRAL regained ~12% body weight after 5 weeks, 118 
while the weight loss seen in IgG control treated mice was  maintained, reaching 119 
~7% below starting weight (Fig. 2d). The significant reduction in fat mass seen with 120 
metformin treatment and control antibody was not seen in the anti-GFRAL group. 121 
(Extended Data Fig. 4d). The delivery of metformin in chow resulted in an initial 122 
reduction in food intake in all metformin treated groups, presumably because of a 123 
taste effect. This reduction in food intake will have affected metformin levels and is 124 
likely to have impacted GDF15 levels with potential to bias the results. However, it is 125 
reassuring to note that any persistence of this would have worked against the 126 
detection of a specific effect of GFRAL antagonism, which was clearly demonstrable.   127 
We undertook indirect calorimetry in metformin- and placebo-treated mice treated with 128 
anti-GFRAL antibody to establish whether there are additional effects on energy 129 
expenditure. Data were analysed by ANCOVA with body weight as the co-variate. 130 
Metformin treatment resulted in a significant increase in metabolic rate which was 131 
blocked by antagonism of GFRAL (Fig. 2e). Thus under conditions where GDF15 132 
levels are increased by metformin, body weight reduction is contributed to by both 133 
reduced food intake and an inappropriately high energy expenditure. 134 
 GDF15 and  glucose homeostasis 135 
To examine the extent to which the insulin sensitising effects of metformin are 136 
dependent on GDF15 we repeated the experiment described in Fig.2a (see Extended 137 
Data Fig. 5), undertaking insulin tolerance testing in metformin and vehicle-treated 138 
GDF15 null mice and their wild type littermates (Fig. 3a). Circulating metformin levels 139 
achieved in both genotypes were identical (Extended Data Fig. 5d) and consistent 140 
with the high end of the human therapeutic range 14.  Metformin significantly increased 141 
insulin sensitivity as assessed by the area under the plasma glucose curve with no 142 
significant effect of genotype (Fig. 3b).  Similarly, metformin reduced fasting blood 143 
glucose and fasting insulin in a GDF15-independent manner (Fig. 3 c,d). 144 
We also undertook oral glucose tolerance testing of metformin treated mice given 145 
either control IgG or anti-GFRAL antibody for 5 weeks (Fig  3e,f, Extended Data Fig. 146 
6a and see Fig. 2d). Although the effect of metformin glucose disposal at OGTT as 147 
assessed by the area under the plasma glucose curve did not reach statistical 148 
significance (2W ANOVA, p=0.072), there was a significant effect of metformin on 149 
insulin, both fasting and AUC after glucose bolus, that was independent of antibody 150 
(Fig. 3 g,h,i,j). 151 
As these mice were of different body weight at the time of assessment (Fig. 2d and 152 
Extended  Data Fig. 3c), we undertook further glucose tolerance testing  in a cohort 153 
of weight matched Gdf15 +/+ and Gdf15-/- mice that had been fed a high fat diet for 2 154 
weeks before receiving a single dose of metformin (300mg/kg) (Fig 3k,l and Extended 155 
Data Fig. 6b-d) In these mice there was a significant effect of metformin upon glucose 156 
(AUC plasma glucose) that was independent of GDF15 (extended Data Fig. 6 e). 157 
Metformin’s effect to lower fasting glucose and insulin and to improve glucose 158 
tolerance appear not to require GDF15. Given the “a priori” expected effect of weight 159 
loss on insulin sensitivity it is worthy of comment that the effect of GDF15 status on 160 
insulin sensitivity as measured by ITT (Fig 3b) fell just short of statistical 161 
significance. In the follow up of the DPP study in non–diabetic individuals, weight 162 
loss after 5 years of metformin therapy was approximately 6.5% of baseline weight5 .  163 
We therefore estimated the effect of a 6.5% weight loss on improvements in fasting 164 
insulin over  5 years in the Ely Study, a prospective observational population-based 165 
cohort study of men (n=465) and women (n=634) in the UK (mean age 52 years, 166 
mean BMI 26 at baseline)15 ,  showing that this magnitude of weight loss was 167 
associated  with a reduction  in fasting plasma insulin (mean ±95% CI)  of -5.74 (-168 
9.03, -2.45) pmol/l  in women and  -8.78 (-16.24, -1.33) in men. We conclude that 169 
while there are GDF15-independent effects of metformin on circulating levels of 170 
glucose and insulin, it is likely that the GDF15 dependent weight loss will make a 171 
contribution to enhancing insulin sensitivity.  172 
 173 
Source of GDF15 production 174 
We examined GDF15 gene expression in a tissue panel obtained from mice fed a high 175 
fat diet (for 4 weeks) and sacrificed 6 hours after a single gavage dose of metformin 176 
(600mg/kg). Circulating concentrations of GDF15 increased ~4-fold compared to 177 
vehicle treated mice (Extended Data Fig. 6f). Gdf15 mRNA was significantly 178 
increased by metformin in small intestine, colon and kidney. (Fig. 4a). In situ 179 
hybridisation studies demonstrated strong Gdf15 expression in crypt enterocytes in 180 
the colon and small intestine and in periglomerular renal tubular cells (Fig. 4b, 181 
Extended Data Fig. 7a, b). We confirmed these sites of tissue expression in HFD fed 182 
mice (those used in Fig 2a), treated with metformin for 11 days (Extended Data Fig. 183 
8).  184 
Further, in human (Fig. 4c) and murine (Fig. 4d) intestinal-derived organoids grown 185 
in 2D transwells and treated with metformin, we saw a significant induction of mRNA 186 
expression and GDF15 protein secretion. 187 
Given the proposed importance of the liver for metformin’s metabolic action it was 188 
notable that the dominant GDF15 expression signal was not from the liver (Fig. 4a, 189 
Extended Data Fig. 7a, Extended Data Fig. 8). To test whether hepatocytes are 190 
capable of responding to biguanide drugs with an increase in GDF15 we incubated 191 
freshly isolated murine hepatocytes (Extended Data Fig. 9a) and  stem-cell derived 192 
human hepatocytes (Extended Data Fig. 9b) with metformin and found  a clear 193 
induction of GDF15 expression.  Additionally, acute administration of the more cell 194 
penetrant biguanide drug phenformin to mice increased circulating GDF15 levels 195 
(Extended Data Fig. 9c) and markedly increased Gdf15 mRNA expression in 196 
hepatocytes (Extended Data Fig. 9d,e). We conclude that biguanides can induce 197 
GDF15 expression in many cell types, but at least when given orally to mice, GDF15 198 
mRNA is most strikingly induced in the distal small intestine, colon and kidney. 199 
GDF15 expression has been reported to be a downstream target of the cellular 200 
integrated stress response (ISR) pathway16-18.Gdf15 mRNA levels were increased in 201 
kidney and colon 24 h after a single oral dose of metformin and these changes 202 
correlated positively with the fold elevation of CHOP mRNA (Extended Data Fig. 203 
10a,b).  As phenformin has broader cell permeability than metformin19  we used it to 204 
explore the effects of biguanides on the ISR and its relationship to GDF15 expression 205 
in cells. In murine embryonic fibroblasts (MEFs), which do not express the organic 206 
cation transporters needed for the uptake of metformin, phenformin (but not 207 
metformin) increased EIF2α phosphorylation, ATF4 and CHOP expression, 208 
(Extended Data Fig. 10c) and GDF15 mRNA (Extended Data Fig. 10d), though the 209 
changes in EIF2a phosphorylation and ATF4 and CHOP expression were modest 210 
compared with those induced by tunicamycin despite similar levels of GDF15 mRNA 211 
induction. Both genetic deletion of ATF4 and siRNA-mediated knockdown of CHOP 212 
significantly reduced phenformin-mediated induction of GDF15 mRNA expression 213 
(Extended Data Fig. 10e,f). In addition, phenformin induction of GDF15 was markedly 214 
reduced by co-treatment with the EIF2α inhibitor, ISRIB but, notably, not by the PERK 215 
inhibitor, GSK2606414 (Extended Data Fig. 10g). Further, GDF15 secretion in 216 
response to metformin in murine duodenal organoids was also significantly reduced 217 
by co-treatment with ISRIB (Extended Data Fig. 10h). However, gut organoids 218 
derived from CHOP null mice are still able to increase GDF15 secretion in response 219 
to metformin (Extended Data Fig. 10i) indicating the existence of CHOP-independent 220 
pathways under some circumstances. The data suggest that the effects of biguanides 221 
on GDF15 expression are at least partly dependent on the ISR pathway but are 222 
independent of PERK. However, the relative importance of components of the ISR 223 
pathway may vary depending on specific cell type, dose and agent used. 224 
Our observations represent a significant advance in our understanding of the action of  225 
metformin, one of the world’s most frequently prescribed drugs. Metformin increases 226 
circulating GLP1 levels20-22 , but its metabolic effects in mice are unimpaired in mice 227 
lacking the GLP-1 receptor 23. Metformin alters the intestinal microbiome24,25  but it is 228 
challenging to firmly establish acausal relationship to the beneficial effects of the drug 229 
26. 230 
 In the work presented herein, we describe a body of data from humans, cells, 231 
organoids and mice that securely establish a major role for GDF15 in the mediation 232 
of metformin’s  beneficial effects  on  energy balance. While these effects likely 233 
contribute to metformin’s role as an insulin sensitizer, metformin continues to have 234 
effects to lower glucose and insulin in the absence of GDF15. 235 
 236 
While there have  been many mechanisms suggested for the glucoregulatory 237 
mechanisms of metformin27   there has been less attention paid to its effects on 238 
weight. Our discoveries relating to metformin’s effects via GDF15 provide a 239 
compelling explanation for this important aspect of metformin action. 240 
It is notable that the lower small intestine and colon are a major site of metformin 241 
induced GDF15 expression. A body of work is emerging which strongly implicates 242 
the intestine as a major site of metformin action. Metformin increased glucose uptake 243 
into colonic epithelium from the circulation28   and a gut-restricted formulation of 244 
metformin had  greater  glucose lowering efficacy than  systemically absorbed 245 
formulations 29 .Our finding that the intestine is a major site of metformin-induced 246 
GDF15 expression provides a further mechanism through which metformin’s action 247 
on the intestinal epithelium  may mediate some of its benefits.  248 
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Figure Legend 328 
Figure 1. Effect of Metformin on circulating GDF15 levels in humans and mice.  329 
a, Paired serum GDF15  concentration in 9 human subjects after 2 weeks of either 330 
placebo or  metformin,  P (95% confidence interval)  by 2-tailed t-test. 331 
b, Plasma GDF15 concentration (mean± SEM) in overweight or obese non-diabetic 332 
participants with known cardiovascular disease randomised to metformin or placebo 333 
in CAMERA, using a mixed linear model. Subject numbers: placebo vs metformin, 334 
respectively, at time points: baseline, n=85 vs n=86; 6 months, n=81 vs n= 71;12 335 
months, n=77 vs n=68; 18 months, n=83 vs n=74. Comparing metformin vs placebo 336 
groups, two-sided p=0.311 at baseline, and p<0.0001 at 6,12 and 18 months 337 
individually. 338 
c, Serum GDF15 levels (mean± SEM) in obese mice measured 2, 4, 8 or 24 hours 339 
after a single oral dose of 300 mg/kg or 600 mg/kg metformin, n=7/group, P by 2-way 340 
ANOVA with Tukey’s correction for multiple comparisons. 341 
 342 
Figure 2. GDF15/GFRAL signalling is required for the weight loss effects of 343 
metformin on a high fat diet. 344 
a, Percentage change in body weight of Gdf15+/+ and Gdf15-/- mice on a high-fat 345 
diet treated with metformin (300mg/kg/day) for 11 days, mean ± SEM, n=6/group 346 
except Gdf15+/+ vehicle n=7, P by 2-way ANOVA with Tukey’s correction for 347 
multiple comparisons. 348 
b, Cumulative food intake of mice as Figure 2a, P by 2-way ANOVA with Tukey’s 349 
correction for multiple comparisons. 350 
c, Percentage change in body weight of Gfral+/+ and Gfral-/-  mice on a high-fat diet 351 
treated with metformin (300mg/kg/day) for 11 days, mean ± SEM, n=6/groups, P  by 352 
2-way ANOVA with Tukey’s correction for multiple comparisons.  353 
d, Percentage change in body weight of metformin-treated obese mice dosed with 354 
an anti-GFRAL antagonist antibody, weekly for 5 weeks (yellow), starting 4 weeks 355 
after initial metformin exposure (grey),mean ± SEM, n=7 Vehicle + control IgG and 356 
Metformin + anti –GFRAL,  n=8 other groups, P by 2-way ANOVA with Tukey’s 357 
correction for multiple comparisons. “calo” = period in which energy expenditure 358 
measured (see Figure 2e), Arrow and “GTT”- timing of oral glucose tolerance test 359 
(see Figure 3e-h). 360 
e, ANCOVA analysis of energy expenditure against body weight of mice treated as in 361 
Figure 2d, n=6 mice/group. Data are individual mice and P for metformin calculated 362 
using ANCOVA with body weight as a covariate and treatment as a fixed factor. 363 
 364 
Figure 3. Effects of metformin on glucose homeostasis. 365 
a, Insulin tolerance test (ITT) (insulin=0.5 U/kg) after 11 days of metformin treatment 366 
(300mg/kg) to high fat  fed Gdf15 +/+ and Gdf15 -/- mice, glucose levels are mean ± 367 
SEM, n=6/group, except Gdf15 -/- vehicle= 7, Gdf15+/+ vehicle= 5.  368 
b, Area under curve (AUC) analysis of glucose over time in Figure 3a, mean ± SEM, 369 
P by 2-way ANOVA , interaction of genotype and metformin p= 0.037. 370 
c, Fasting glucose (time 0) of ITT in Figure 3a, mean ± SEM, P by 2-way ANOVA, 371 
effect of genotype p= 0.144, interaction of genotype and metformin p= 0.988. 372 
d,  Fasting insulin (time 0) of ITT in Figure 3a, mean ± SEM, P by 2-way ANOVA, 373 
effect of genotype p= 0.131, interaction of genotype and metformin p 0.056. 374 
e, f, Glucose over time after oral glucose tolerance test  (GTT) in metformin treated 375 
obese mice given either IgG (e ) or anti –GFRAL (f) once weekly for 5 weeks (as 376 
Figure 2d). AUC analysis by 2-way ANOVA, effect of antibody p= 0.031, effect of 377 
metformin p= 0.072, interaction of antibody and metformin p 0.91. 378 
g, h, Insulin (mean ± SEM) over time after GTT in mice as Figure 3e and f. 379 
i, Fasting insulin (time 0) of GTT in mice as Figure 3e and f, mean ± SEM, P by 2-380 
way ANOVA, effect of antibody p= 0.544, interaction of genotype and metformin p 381 
0.691. 382 
j, AUC analysis of insulin over time in  Figure 3g and h, mean ± SEM,  P by 2 -way 383 
ANOVA, effect of antibody p= 0.197, interaction of genotype and metformin p 0.607. 384 
k, l, Glucose (mean ± SEM) over time after intraperitoneal GTT in high fat fed mice 385 
given single dose of oral metformin ( 300mg/kg) 6 hrs before GTT,  n=8/group.  386 
 387 
Figure 4.  Metformin increases GDF15 expression in the enterocytes of distal 388 
intestine and the renal tubular epithelial cells. 389 
a, Gdf15 mRNA expression (normalised to expression levels of ActB) in tissues from 390 
high-fat fed wild type mice 6 hrs after single dose of oral metformin (600mg/kg), 391 
mean ± SEM, n=7/group,  P value (95% confidence interval) by two tailed t-test. 392 
b, In situ hybridization for Gdf15 mRNA (red spots) n= 7 per group. Representative 393 
images from the mouse with circulating GDF15 level closest to group median, either 394 
vehicle-treated (panel 1a,1b,1c, blue box) or metformin-treated ( panels 2a, 2b, 2c, 395 
red box). Mice from groups described in Figure 4a.  396 
c, Gdf15 mRNA expression (left panel) and GDF15 protein in supernatant (right 397 
panel) of human derived 2D monolayer rectal organoids treated with metformin. 398 
Each colour represents independent experiments (n= 4), mean ± SD, P value (95% 399 
confidence interval) by two-tailed t-test.  400 
d, GDF15 protein in supernatants of mouse-derived 2D monolayer duodenal (left 401 
panel) and ileal (right panel) organoids treated with metformin. Each colour 402 
represents independent experiment (duodenal n= 5, ileal n=3),mean ± SD, P value 403 
(95% confidence interval) by two-tailed t-test.  404 
  405 
 406 
 407 
 408 
 409 
 410 
Methods. 411 
Human Studies. 412 
We analysed samples from 9 participants from a study with a placebo-controlled, 413 
double-blind crossover design (previously described in12 ).  In brief, placebo or 414 
metformin (week 1, 500mg twice daily; week, 2 1000mg twice daily) were 415 
administered following a six week period of washout. Samples were collected in the 416 
morning after overnight fasting.  The study was approved by the Mayo Clinic 417 
Institutional Review Board and all participants provided written, informed consent 418 
(NCT01956929). 419 
CAMERA was a randomized, double-blinded, placebo-controlled trial designed to 420 
investigate the effect of metformin on surrogate markers of cardiovascular disease in 421 
patients without diabetes, aged 35 to 75, with established coronary heart disease 422 
and a large waist circumference (≥ 94cm in men, ≥80 cm in women) 423 
(NCT00723307). This single-centre trial enrolled 173 adults who were followed up for 424 
18 months each. A detailed description of the trial and its results has been published 425 
previously13. In brief, participants were randomized 1:1 to 850mg metformin or 426 
matched placebo twice daily with meals. Participants attended six monthly visits after 427 
overnight fasts and before taking their morning dose of metformin. Blood samples 428 
collected during the trial were centrifuged at 4 degrees Celsius soon after sampling, 429 
separated and stored at -80°C 430 
All participants provided written informed consent. The study was approved by the 431 
Medicines and Healthcare Products Regulatory Agency and West Glasgow 432 
Research Ethics Committee, and done in accordance with the principles of the 433 
Declaration of Helsinki and good clinical practice guidelines. 434 
Serum GDF15 assays were completed by the Cambridge Biochemical Assay 435 
Laboratory, University of Cambridge. Measurements were undertaken with 436 
antibodies & standards from R&D Systems (R&D Systems Europe, Abingdon UK) 437 
using a microtiter plate-based two-site electrochemiluminescence immunoassay 438 
using the MesoScale Discovery assay platform (MSD, Rockville, Maryland, USA).  439 
Mouse Studies. 440 
Studies were carried out in two sites; NGM Biopharmaceuticals, California, USA and 441 
University of Cambridge, UK.  442 
At NGM, all experiments were conducted with NGM IACUC approved protocols and 443 
all relevant ethical regulations were complied with throughout the course of the 444 
studies, including efforts to reduce the number of animals used. Experimental 445 
animals were kept under controlled light (12hour light and 12hour dark cycle, dark 446 
6:30 pm - 6:30 am), temperature (22 ± 3°C) and humidity (50% ± 20%) conditions. 447 
They were fed ad libitum on 2018 Teklad Global 18% Protein Rodent Diet containing 448 
24 kcal% fat, 18 kcal% protein and 58 kcal% carbohydrate, or on high fat rodent diet 449 
containing 60 kcal% fat, 20 kcal% protein and 20 kcal% carbohydrates from 450 
Research Diets D12492i,( New Brunswick NJ 089901 USA) herein referred to as 451 
“60%HFD”. 452 
In Cambridge, all mouse studies were performed in accordance with UK Home 453 
Office Legislation regulated under the Animals (Scientific Procedures) Act 1986 454 
Amendment, Regulations 2012, following ethical review by the University of 455 
Cambridge Animal Welfare and Ethical Review Body (AWERB). They were 456 
maintained  in a 12-hour light/12-hour dark cycle (lights on 0700–1900), 457 
temperature-controlled (22°C) facility, with ad libitum access to food (RM3(E) 458 
Expanded chow, Special Diets Services, UK) and water. Any mice bought from an 459 
outside supplier were acclimatised in a holding room for at least one week prior to 460 
study. During study periods they were fed ad libitum high fat diet, either D12451i (45 461 
kcal% fat, 20 kcal% protein and 35 kcal% carbohydrates, herein referred to as 462 
“45%HFD”)  or  D12492i ( Research Diets, as above) as highlighted in individual 463 
study. 464 
Sample sizes were determined on the basis of homogeneity and consistency of 465 
characteristics in the selected models and were sufficient to detect statistically 466 
significant differences in body weight, food intake and serum parameters between 467 
groups. Experiments were performed with animals of a single gender in each study. 468 
Animals were randomized into the treatment groups based on body weight such that 469 
the mean body weights of each group were as close to each other as possible, but 470 
without using excess number of animals. No samples or animals were excluded from 471 
analyses. Researchers were not blinded to group allocations. 472 
Mouse study 1. Acute two- dose metformin study in high fat diet fed mice.   473 
Male C57Bl6/J mice fed 60% HFD for 17 weeks were studied aged 23 weeks ( body 474 
weight, mean±SEM, 45.6±0.8g). Metformin (Sigma-Aldrich # 1396309) was 475 
reconstituted in water at 30 mg/ml for oral gavage and given in early part of light 476 
cycle. Terminal blood was collected by cardiac puncture into EDTA- coated tubes.  477 
GDF15 levels were measured using Mouse/Rat GDF15 Quantikine ELISA Kit (Cat#: 478 
MGD-150, R&D Systems, Minneapolis, MN) according to the manufacturers’ 479 
instructions.  RNA was isolated from tissues using the Qiagen RNeasy Kit.  RNA was 480 
quantified and 500ng was used for cDNA synthesis (SuperScript VILO 11754050 481 
ThermoFisher) followed by qPCR. All Taqman probes were purchased from Applied 482 
Biosystems. All genes are expressed relative to 18s control probe and were run in 483 
triplicate.  484 
 485 
Mouse study 2. Acute metformin study in chow fed animals. 486 
2.i) ad libitum group. 487 
Male C57BL6/J mice (Charles River, Margate, UK) were studied at 11 weeks old. 488 
500mg of metformin was dissolved in 20 mls of water to make a working stock of 489 
25mg/ml.  1 hr after onset of light cycle mice received a single dose by oral gavage 490 
of either metformin at 300mg/kg dose (Sigma, PHR1084-500MG) or matched 491 
volume of vehicle (water).  Weight (mean± SEM) of control and treatment groups 492 
were 27.2 ± 0.3 vs 26.7 ± 0.2 g, respectively on day of study.  After gavage mice 493 
were returned to an individual cage and were sacrificed at relevant time point by 494 
terminal anaesthesia (Euthatal by Intraperitoneal injection). Blood  was collected  495 
into Sarstedt Serum Gel 1.1ml Micro Tube, left  for 30mins at room temperature, 496 
spun for 5mins at 10k at 40C before being frozen and stored at -80oC until assayed. 497 
Mouse GDF15 levels were measured using a Mouse GDF15 DuoSet ELISA (R&D 498 
Systems) which had been modified to run as an electrochemiluminescence assay on 499 
the Meso Scale Discovery assay platform. 500 
2.ii) fasted group. 501 
Mice, conditions and methods as in (2.i) except male mice studied at 9 weeks old 502 
and that 12 hr prior to administration of metformin mice and bedding were 503 
transferred to new cages with no food in hopper. Weight (mean± SEM) after fasting 504 
and on day of gavage were 22.3±0.5 g and 23.2±0.7g for control and treatment 505 
groups, respectively. 506 
Mouse study 3. Metformin to high fat diet fed Gdf15 -/- mice and wild type 507 
controls. 508 
C57BL/6N-Gdf15tm1a(KOMP)Wtsi/H  mice  ( herein referred to as “Gdf15 -/- mice“) 509 
were obtained from the MRC Harwell Institute which distributes these mice on behalf 510 
of the European Mouse Mutant Archive (www.infrafrontier.eu). The MRC Harwell 511 
Institute is also a member of the International Mouse Phenotyping Consortium 512 
(IMPC) and has received funding from the MRC for generating and/or phenotyping 513 
the C57BL/6N-Gdf15tm1a(KOMP)Wtsi/H mice. The research reported in this 514 
publication is solely the responsibility of the authors and does not necessarily 515 
represent the official views of the Medical Research Council. Associated primary 516 
phenotypic information may be found at www.mousephenotype.org. Details of the 517 
alleles have been published 30-32. 518 
Experimental cohorts of male Gdf15 -/- and wild type mice were generated by het x 519 
het breeding pairs. Mice were aged between 4.5 and 6.5 months.  One week prior to 520 
study start mice were single housed and 3 days prior to first dose of metformin 521 
treatment, mice were transferred from standard chow to 60% high fat diet.  On day of 522 
first gavage body weight of study groups (mean±SEM) were 38.2±1.0g vs 38.8±0.6g 523 
for wild type vehicle and metformin treatment respectively, and 37.9±0.8g vs 524 
37.0±1.4g for Gdf15 -/-  vehicle and metformin treatment respectively. Each mouse 525 
received a daily gavage of either vehicle or metformin for 11 days, and their body 526 
weight and food intake measured daily in the early part of the light cycle. One data 527 
point of 25 food intake points  collected on  day11  of study was lost due to technical 528 
error (mouse; Gdf15 +/+ metformin). On day 11 mice were sacrificed by terminal 529 
anaesthesia 4 hours post gavage, blood was obtained as in study 2. Tissues were 530 
fresh frozen on dry ice and kept at -800C until day of RNA extraction. 531 
 532 
Mouse study 4. Metformin to high fat diet fed Gfral -/- mice. 533 
Gfral-/- mice were purchased from Taconic (#TF3754) on a mixed 129/SvEv-C57BL/6 534 
background and backcrossed for 10 generations to >99% C57BL/6 background at 535 
NGM’s animal facility. Experimental cohorts were generated by het X het breeding 536 
pairs. Study design as Study 3, except terminal blood was collected into EDTA- 537 
coated tubes. 538 
Mouse study 5. Anti GFRAL antibody to metformin treated high fat diet fed 539 
mice.  540 
Anti-GFRAL antibody generation. Anti-GFRAL monoclonal antibodies were 541 
generated by immunizing C57Bl/6 mice with recombinant purified GFRAL ECD-hFc 542 
fusion protein, which was purified via sequential protein-A affinity and size exclusion 543 
chromatography (SEC) techniques using MabSelect SuRe and Superdex 200 544 
purification media respectively (GE Healthcare), as described in patent number 545 
US10174119B2, https://patents.google.com/patent/US10174119B2/en.  An in-house 546 
pTT5 hIgK hIgG1 expression vector was engineered to include the DEVDG 547 
(caspase-3) proteolytic site N-terminal to the Fc domain. The heavy chains of anti-548 
GFRAL mAbs were subcloned via EcoR1/HindIII sites of in-house engineered pTT5 549 
hIgK hIgG1 caspase-cleavable vector. Light chains of anti-GFRAL mAbs were also 550 
subcloned within the EcoR1/HindIII sites in the pTT5 hIgK hKappa vector. The 551 
antibody were transiently expressed in Expi293 cells (Thermo Fisher Scientific) 552 
transfected with the pTT5 expression vector, and purified from conditioned media by 553 
sequential protein-A affinity and size-exclusion chromatographic (SEC) methods 554 
using MabSelect SuRe and Superdex 200 purification media respectively (GE 555 
Healthcare). All purified antibody material was verified endotoxin-free and formulated 556 
in PBS for in vitro and in vivo studies. Characterization of anti-GFRAL functional 557 
blocking antibodies was carried out using a cell-based RET/GFRAL luciferase gene 558 
reporter assays, in vitro binding studies (ELISA and Biacore) and in vivo studies, as 559 
described in patent number; US10174119B2, 560 
https://patents.google.com/patent/US10174119B2/en).  561 
In all studies with anti-GFRAL, purified recombinant non-targeting IgG on the same 562 
antibody framework was used as control. Metformin was mixed with food paste 563 
made from the 60 kcal% fat diet (Research diet# D12492) using a food blender at a 564 
concentration to achieve an approximate consumption of 300mg/kg metformin per 565 
day per mouse. Male animals were single housed throughout and at start of study  566 
period body weight ( mean ±SEM) was 43.7±1.4g, 42.3±1.4g, 41.9±1.1g,43.3±1.3g,  567 
veh + control IgG, veh +anti-GFRAL, metformin + control IgG,  Metformin + anti-568 
GFRAL, respectively. Recombinant antibodies were administered by subcutaneous 569 
injection in the early part of the light cycle. Body composition (lean and fat mass) 570 
was analyzed by ECHO MRI M113 mouse system (Echo Medical Systems). The 571 
metabolic parameters oxygen consumption (VO2) and carbon dioxide production 572 
(VCO2) were measured by an indirect calorimetry system (LabMaster TSE System, 573 
Germany) in open circuit sealed chambers. Measurements were performed for the 574 
dark (from 6pm to 6am) or light (from 6am to 6pm) period under ad libitum feeding 575 
conditions. Mice were placed in individual metabolic cages and allowed to acclimate 576 
for a period of 24 hours prior to data collection in every 30 minutes. 577 
 Finally, mice underwent a glucose tolerance test. Mice were fasted for 6 hours 578 
(7am-1pm) in a clean cage. Blood samples (~30 ul) were collected as baseline prior 579 
to oral glucose tolerance test.  Mice were orally gavaged with 1 g/kg of 20% glucose 580 
solution with a dosing volume of 5 mL/kg. Blood samples were then collected 581 
through tail nick into K2EDTA-coated tubes (SARSTEDT Microvette; REF 582 
20.1278.100) at 15, 30, 60 and 120 minutes post glucose challenge. Blood samples 583 
were centrifuged at 4 °C and the separated plasma are stored at  -20 °C until used 584 
for plasma glucose and insulin assays. Glucose assay reagents obtained from 585 
Wako, Cat# 439-90901, and the insulin ELISA kit obtained from ALPCO, Cat# 80-586 
INSMSU-E01. 587 
 588 
Mouse study 6. Insulin tolerance test after metformin treatment to high fat diet 589 
fed Gdf15-/- and wild type controls. 590 
Mice generation and protocol as Study 3, except aged 4 to 6 months. On day of first 591 
gavage body weights (mean±SEM) of study groups were 35.1±1.2g; 35.05±1.2g for 592 
wild type Vehicle  and Metformin treatment respectively, and 35.08±1.02g; 593 
35.02±1.47g for Gdf15-/-  Vehicle  and Metformin treatment respectively. On day 11, 594 
after final dose of metformin mice were fasted for 4 hours. Baseline venous blood 595 
sample was collected into heparinised capillary tube for insulin measurement and 596 
blood glucose was measured using approximately 2 μl blood drops using a 597 
glucometer (AlphaTrak2; Abbot Laboratories) and glucose strips (AlphaTrak2 test 2 598 
strips, Abbot Laboratories, Zoetis) .Mice were given intraperitoneal injection of insulin 599 
(0.5U/kg mouse, Actrapid, NovoNordisk Ltd) and serial mouse glucose levels 600 
measured at time points indicated. Mice were sacrificed by terminal anaesthesia as 601 
in Study 2. Mouse insulin was measured using a 2-plex Mouse Metabolic 602 
immunoassay kit from Meso Scale Discovery Kit (Rockville, MD, USA), performed 603 
according to the manufacturer’s instructions and using calibrators provided by MSD. 604 
Serum metformin levels were quantified using a stable isotope dilution LC-MS/MS 605 
method described previously33 . 606 
Mouse study 7. Glucose tolerance test after single dose metformin treatment 607 
to high fat diet fed Gdf15-/- and wild type controls. 608 
Mice generation as Study 3, except female mice aged 3.5 to 5.5 months. 2 groups of 609 
mice (Gdf15+/+ and Gdf15-/- littermates, body weight (mean±S.E.M), 24.1 ±1.4g  vs 610 
24.3±1.3g , respectively) were fed 60% HFD for 2 weeks. Each genotype was then 611 
further split into vehicle or metformin (300mg/kg) treatment group, given a single 612 
gavage dose at 8am and fasted for 6 hrs. At time of GTT, body weights 613 
(mean±S.E.M) of study groups were 26.4.1±1.5g; 26.5±1.0g for wild type Vehicle  614 
and Metformin treatment respectively, and 25.6±1.2g; 27.1±1.3g for Gdf15-/-  615 
Vehicle  and Metformin treatment respectively (1 way ANOVA, p=0.8722). Baseline 616 
testing as mouse study 6. Mice then received a single dose of 20% glucose via 617 
intraperitoneal route (2mg/g dose) with serial measurement of glucose levels 618 
measured at time points indicated. Sacrifice and insulin analysis as mouse study 6. 619 
 620 
Mouse study 8. Acute single high dose metformin study in high fat diet fed 621 
wild type mice. 622 
Male C57BL6/J mice (Charles River,Margate, UK) aged 14 weeks  were switched 623 
from standard chow  to  45 %HFD fat (D12451i) for 1 week then 60%HFD (D12492i,) 624 
for 3 weeks). At time of study (18 weeks old) body weights (mean ±SEM) were 40.4± 625 
1.2g vs 41.1±1.3g, vehicle vs metformin group, respectively.  500mg of metformin 626 
(Sigma, PHR1084-500MG) was dissolved in 8.35 mls of water to make a working 627 
stock of 60mg/ml.  Mice received a single dose by oral gavage of either 600mg/kg 628 
metformin or matched volume of vehicle (water). They were returned to ad lib 60 % 629 
fat diet and 6 hrs later blood was collected as study 2.  Tissue samples for RNA 630 
analysis were collected into Lysing Matrix D homogenisation tube (MP Biomedicals) 631 
on dry ice and stored at -800C until processed. Intestine between pylorus of stomach 632 
and caecum was laid out into 3 equal parts, with tissue taken from mid-point of each 633 
third labelled as “proximal”, “ middle” and “ distal” (adapted from 34). Colon section 634 
was from mid-point between caecum and anus. Tissue for in-situ hybridisation were 635 
dissected and placed into 10% formalin/PBS for 24hr at room temp, transferred to 636 
70% ethanol, and processed into paraffin. 5μm sections were cut and mounted onto 637 
Superfrost Plus (Thermo-Fisher Scientific). Detection of Mouse Gdf15 was 638 
performed on FFPE sections using Advanced Cell Diagnostics (ACD) RNAscope® 639 
2.5 LS Reagent Kit-RED (Cat No. 322150) and RNAscope® LS 2.5 Probe Mm-640 
Gdf15-O1 (Cat No. 442948) (ACD, Hayward, CA, USA). Briefly, sections were baked 641 
for 1 hour at 60oC before loading onto a Bond RX instrument (Leica Biosystems). 642 
Slides were deparaffinized and rehydrated on board before pre-treatments using 643 
Epitope Retrieval Solution 2 (Cat No. AR9640, Leica Biosystems) at 95°C for 15 644 
minutes, and ACD Enzyme from the LS Reagent kit at 40oC for 15 minutes. Probe 645 
hybridisation and signal amplification was performed according to manufacturer’s 646 
instructions. Fast red detection of mouse Gdf15 was performed on the Bond RX 647 
using the Bond Polymer Refine Red Detection Kit (Leica Biosystems, Cat No. 648 
DS9390) according to the ACD protocol. Slides were then counterstained with 649 
haematoxylin, removed from the Bond RX and were heated at 60oC for 1 hour, 650 
dipped in Xylene and mounted using EcoMount Mounting Medium (Biocare Medical, 651 
CA, USA. Cat No. EM897L).  652 
Slides imaged on an automated slide scanning microscope (Axioscan Z1 and 653 
Hamamatsu orca flash 4.0 V3 camera) using a 20x objective with a numerical 654 
aperture of 0.8. Hybridisation specificity was confirmed by the absence of staining in 655 
Gdf15-/- mice. 656 
RNA extraction was carried out with approximately 100mg of tissue in 1ml Qiazol 657 
Lysis Reagent (Qiagen 79306l) using Lysing Matrix D homogenisation tube and 658 
Fastprep 24 Homogeniser (MP Biomedicals) and Qiagen RNeasy Mini kit (Cat no 659 
74106) with DNase1 treatment following manufacturers’ protocols. 500ng of RNA 660 
was used to generate cDNA using Promega M-MLV reverse transcriptase followed 661 
by TaqMan qPCR in triplicates for GDF15. Samples were normalised to Act B. 662 
TaqMan Probes: Mm00442228 m1 GDF15, Mm02619580_g1 Act B, TaqMan;2X 663 
universal PCR Master mix (Applied Biosystems Thermo Fisher 4318157); 664 
QuantStudio 7 Flex Real time PCR system (Applied Biosystems Life Technologies) 665 
Mouse study 9. Acute phenformin study in standard chow-fed wild type 666 
animals. 667 
Male C57BL6/J mice aged 14 weeks with supplier, protocol and methods as study 2, 668 
except phenformin (Sigma PHR1573-500mg) used instead of metformin.  669 
Organoid studies. 670 
Duodenal and ileal mouse organoid line generation, maintenance and 2D culture 671 
was performed as previously described35. CHOP null mice were kind gift of Dr Jane 672 
Goodall (University of Cambridge), with line  from Jackson Laboratory,Maine  673 
(B6.129S(Cg)-Ddit3tm2.1Dron/J, Stock No: 005530 ) Human rectal organoids 674 
(experiments approved by the Research Ethics Committee under license number 675 
09/H0308/24) were generated from fresh surgical specimens (Tissue Bank 676 
Addenbrooke’s Hospital (Cambridge, UK)) following a modified protocol 35,36. Briefly 677 
rectal tissue was chopped into 5mm fragments and incubated in 30 mM EDTA for 678 
3x10mins, with tissue shaken in PBS after each EDTA treatment to release intestinal 679 
crypts. The isolated crypts were then further digested using TrypLE (Life 680 
Technologies) for 5 mins at 37⁰C to generate small cell clusters. These were then 681 
seeded into basement membrane extract (BME, R&D technology), with 20 μl domes 682 
polymerised in multiwell (48) dishes for 30-60 mins at 37⁰C. Organoid medium (Sato 683 
et al 2011) was then overlaid and changed 3 times per week. Human organoids were 684 
passaged every 14-21 days using TrypLE digestion for 15 mins at 37⁰C, followed by 685 
mechanical shearing with rigorous pipetting to breakup organoids into small clusters 686 
which were then seeded as before in BME. For transwell experiments TrypLE 687 
digested organoids were seeded onto matrigel (Corning) coated (2% for 60 mins at 688 
37⁰C) polyethylene Terephthalate cell culture inserts, pore size 0.3 μm (Falcon) in 689 
organoid medium supplemented with Y-27632 (R&D technology). Organoids were 690 
observed through the transparent cell inserts to ensure 2D culture formation 691 
(allowing apical cell access for drug treatments). Medium was changed after 2 days 692 
and then switched on day 3 to a differentiation medium with wnt3A conditioned 693 
medium reduced to 10% and SB202190 / nicotinamide omitted from culture for 5 694 
days.  695 
For GDF 15 secretion experiments 2D cultured organoid cells were treated for 24 hrs 696 
with indicated drugs, with medium then collected and GDF15 measured at the Core 697 
Biochemical Assay Laboratory (Cambridge) using the human or mouse  GDF15 698 
assay kit as outlined in CAMERA human study and mouse study 2 above. 699 
RNA was extracted using TRI reagent (Sigma), with any contaminated DNA 700 
eliminated using DNA free removal kit (Invitrogen). Purified RNA was then reverse 701 
transcribed using superscript II (Invitrogen) as per manufacturer’s protocol. RT-702 
qPCR was performed on a QuantStudio 7 (Applied Biosystems) using Fast Taqman 703 
mastermix and the following probes (Applied Biosystems); Human GDF15 704 
(Hs00171132_m1), Human ACTB (Hs01060665_g1). Gene expression was 705 
measured relative to β-actin in the same sample using the ΔCt method, with fold (cf. 706 
control) shown for each experiment.  707 
Hepatocyte studies.  708 
Primary mouse hepatocyte isolation and culture. 709 
Hepatocytes from 8-12 week old C57B6J male mice were isolated by retrograde, 710 
non-recirculating in situ collagenase liver perfusion. In brief: livers were perfused with 711 
modified Hanks medium without calcium (NaCl- 8.0 g/L; KCl- 0.4 g/L; MgSO4.7H2O- 712 
0.2 g/L; Na2HPO4.2H2O- 0.12 g/L; KH2PO4- 0.12 g/L; Hepes- 3 g/L; EGTA- 0.342 713 
g/L; BSA- 0.05 g/L) followed by digestion with perfusion media supplemented with 714 
calcium (CaCl2.2H2O- 0.585 g/L) and 0.5mg/ml of collagenase IV (Sigma, C5138). 715 
The digested liver was removed and washed using chilled DMEM:F12 (Sigma) 716 
medium containing 2 mM L-glutamine, 10 % FBS, 1%  penicillin/streptomycin 717 
(Invitrogen). Viable cells were harvested by Percoll (Sigma) gradient. The final pellet 718 
was resuspended in the same DMEM:F12 media. Cell viability was greater than 719 
90%. Hepatocytes were plated onto primaria plates (Corning). Hepatocytes were 720 
allowed to recover and attach for 4-6 hr before replacement of the medium overnight 721 
prior to stress treatments the following day for the times and concentrations 722 
indicated. 723 
Generation and culture of iPSC derived human hepatocytes. 724 
The human induced pluripotent cell (hiPSC) line A1ATDR/R used in this work was 725 
derived as previously described 37,38 under approval by the regional research ethics 726 
committee (reference number 08/H0311/201). hiPSCs were maintained in Essential 727 
8 chemically defined media39 3supplemented with 2ng/ml Tgf-ß (R&D) and 25ng/ml 728 
FGF2 (R&D), and cultured on plates coated with 10µg/ml Vitronectin XFTM 729 
(STEMCELL Technologies). Colonies were regularly passaged by short-term 730 
incubation with 0.5mM EDTA in PBS. For hepatocyte differentiation, colonies were 731 
dissociated into single cells following incubation with StemPro™ Accutase™ Cell 732 
Dissociation Reagent (Gibco) for 5 minutes at 37°C. Single cell suspensions were 733 
seeded on plates coated with 10µg/ml Vitronectin XFTM (STEMCELL Technologies) 734 
in maintenance media supplemented with 10µM ROCK Inhibitor Y-27632 735 
(Selleckchem) and grown for up to 72h prior to differentiation. Hepatocytes were 736 
differentiated as previously reported40, with minor modifications as listed. Briefly, 737 
following endoderm differentiation, anterior foregut specification was achieved after 5 738 
days of culture with RPMI-B27 differentiation media supplemented with 50ng/ml 739 
Activin A (R&D)40 . Foregut cells were further differentiated into hepatocytes with 740 
HepatoZYME-SFM (Gibco) supplemented with 2mM L-glutamine (Gibco), 1% 741 
penicillin-streptomycin (Gibco), 2% non-essential amino acids (Gibco), 2% 742 
chemically defined lipids (Gibco), 14μg/ml of insulin (Roche), 30μg/ml of transferrin 743 
(Roche), 50 ng/ml hepatocyte growth factor (R&D), and 20 ng/ml oncostatin M 744 
(R&D), for up to 27 days.  745 
 746 
Cellular studies on integrated stress response. 747 
Chemicals and Reagents. 748 
Tunicamycin and ISRIB were purchased from Sigma-Aldrich. Metformin and 749 
Phenformin was purchased from Cayman Chemicals and GSK2606414 from 750 
Calbiochem. The antibody for GDF15 and CHOP (sc-7351) were obtained from 751 
Santa Cruz. Phospho S51 EIF2 (ab32157) and Calnexin (ab75801) were 752 
purchased from Abcam. The antibody for ATF4 was a kind gift from Dr David Ron 753 
(CIMR, Cambridge). 754 
Eukaryotic cell lines and treatments. 755 
Mouse embryonic fibroblast (MEF) cells lines were obtained from David Ron 756 
(CIMR/IMS, Cambridge) and maintained as previously described18. MEFs were 757 
transfected with 30 nM control siRNA or a smartpool on-target plus siRNA for mouse 758 
CHOP (Dharmacon - L-062068-00-0005) using Lipofectamine RNAi MAX 759 
(Invitrogen) according to the manufacturer’s instruction. 48 h post siRNA 760 
transfection, cells were processed for RNA and protein expression analysis. All cells 761 
were maintained at 37 °C in a humidified atmosphere of 5 % CO2 and seeded onto 762 
6- or 12-well plates prior to stress treatments for the times and concentrations 763 
indicated. Vehicle treatments (e.g. DMSO) were used for control cells when 764 
appropriate.  765 
RNA isolation/cDNA synthesis/Q-PCR. 766 
Following treatments, cells were lysed with Buffer RLT (Qiagen) containing 1 % 2-767 
Mercaptoethanol and processed through a Qiashredder with total RNA extracted 768 
using the RNeasy isolation kit according to manufacturer’s instructions (Qiagen). 769 
RNA concentration and quality was determined by Nanodrop. 400 ng - 500 ng of 770 
total RNA was treated with DNase1 (Thermofisher Scientific) and then converted to 771 
cDNA using MMLV Reverse Transcriptase with random primers (Promega). 772 
Quantitative RT-PCR was carried out with either TaqMan™ Universal PCR Master 773 
Mix or SYBR Green PCR master mix on the QuantStudio 7 Flex Real time PCR 774 
system (Applied Biosystems). All reactions were carried out in either duplicate or 775 
triplicate and Ct values were obtained. Relative differences in the gene expression 776 
were normalized to expression levels of housekeeping genes, HPRT or GAPDH for 777 
cell analysis, using the standard curve method. Primers used for this study: mouse 778 
GDF15 (Mm00442228_m1 – ThermoFisher Scientific), human GDF15 779 
(Hs00171132_m1 - ThermoFisher Scientific), human GAPDH (Hs02758991_g1 – 780 
ThermoFisher Scientific), mouse HPRT (Forward – AGCCTAAGATGAGCGCAAGT, 781 
reverse - GGCCACAGGACTAGAACACC) 782 
Immunoblotting. 783 
Following treatments, cells were washed twice with ice cold D-PBS and proteins 784 
harvested using RIPA buffer supplemented with cOmplete protease and PhosStop 785 
inhibitors (Sigma). The lysates were cleared by centrifugation at 13 000 rpm for 15 786 
min at 4 °C, and protein concentration determined by a Bio-Rad DC protein assay. 787 
Typically, 20-30 g of protein lysates were denatured in NuPAGE 4× LDS sample 788 
buffer and resolved on NuPage 4-12 % Bis-Tris gels (Invitrogen) and the proteins 789 
transferred by iBlot (Invitrogen) onto nitrocellulose membranes. The membranes 790 
were blocked with 5 % nonfat dry milk or 5 % BSA (Sigma) for 1 h at room 791 
temperature and incubated with the antibodies described in the reagents section. 792 
Following a 16 h incubation at 4 °C, all membranes were washed five times in Tris-793 
buffered saline-0.1% Tween-20 prior to incubation with horseradish peroxidase 794 
(HRP)-conjugated anti-rabbit immunoglobulin G (IgG), HRP-conjugated anti-mouse 795 
IgG (Cell Signalling Technologies). The bands were visualized using Immobilon 796 
Western Chemiluminescent HRP Substrate (Millipore). All images were acquired on 797 
the ImageQuant LAS 4000 (GE Healthcare). 798 
Statistical analyses. 799 
CAMERA data were analysed using a mixed linear model with restricted maximum 800 
likelihood to investigate the metformin effect on GDF-15. This is analogous to 801 
conducting a repeated measures ANOVA, but is a more flexible analysis and allows 802 
for missing observations within subject. The 0-18 months difference in weight and 803 
GDF15 correlation was tested using Spearman’s coefficient. CAMERA data were 804 
analysed using STATA version 15.1. 805 
 Other statistical analyses were performed using Prism 7 and Prism 8, using 806 
unpaired 2 tailed t-tests ,  or 2-way ANOVA, with multiple comparison adjustment by 807 
Tukey’s  or Sidak’s test. Metabolic rate was determined using ANCOVA with energy 808 
expenditure as the dependent variable, body weight as a covariate and treatment as 809 
a fixed factor. ANCOVA and analyses of glucose and insulin tolerance testing in 810 
mice were performed using SPSS 25 (IBM). 811 
 812 
 813 
Data availability.  814 
The data that support the findings of this study are available from the corresponding 815 
authors upon request. The CAMERA trial dataset is held at the University of 816 
Glasgow and is available on request from the investigators subject to a signed 817 
agreement operating within the confines of the original ethics application. 818 
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Extended Data Figures Legends. 922 
Extended Data Figure 1. Expanded CAMERA data set. 923 
a, Linear association between change in body weight and change in plasma GDF15 924 
between 0 and 18 months among metformin treated participants (n=74, Spearman 925 
correlation r=-0.26, two-sided p=0.024). Red line is linear regression slope, and grey 926 
area is 95% confidence interval for slope. 927 
b, Absolute and relative differences in plasma GDF15 concentration between 928 
metformin and placebo groups at each time point (total 625 observations in 173 929 
participants). 930 
c,d, Individual measures of plasma GDF15 levels in placebo group (c)  and 931 
metformin group (d)  over time. 932 
e, Plasma GDF15 concentration (95%CI) in overweight or obese non-diabetic 933 
participants with known cardiovascular disease randomised to metformin or placebo 934 
in CAMERA; modelled using a mixed linear model as per Figure 1 and grouped as 935 
“all participants” and “ all participants not reporting diarrhoea and vomiting”. Model 936 
includes all participants 937 
 938 
Extended Data Figure 2.Effect of single oral dose of metformin in chow fed 939 
mice.  940 
Serum GDF15 levels in male mice measured 2, 4, or 8 hours after a single gavage 941 
dose of metformin (300mg/kg). a, mice ad libitum overnight fed prior to gavage. b, 942 
mice fasted for 12 hour prior to gavage. Data are mean ± SEM (a; n=6/group, b; n= 943 
4/group); P by 2-way ANOVA with Tukeys correction for multiple comparisons. 944 
 945 
Extended Data Figure 3. Body weight changes with metformin treatment in 946 
mice with disrupted GDF15-GFRAL signalling.  947 
a, Absolute body weight  in Gdf15 
+/+
 and Gdf15 
-/-
 mice on a high-fat diet treated with 948 
metformin (300mg/kg/day) for 11 days, mice as Figure 2a. Data are mean ± SEM, P 949 
by 2-way ANOVA with Tukey’s correction for multiple comparisons. 950 
b, Absolute body weight in high fat diet fed Gfral 
+/+
 and Gfral 
-/-
  mice  given oral 951 
dose of metformin  (300mg/kg) once daily for 11 days, mice as Figure 2c. Data are 952 
mean ± SEM.  953 
c, Absolute body weight of metformin-treated, obese mice dosed with an anti-GFRAL 954 
antagonist antibody or with control IgG  weekly for 5 weeks starting 4 weeks after 955 
initial metformin exposure, mice as Figure 2d. Data are mean ± SEM.  P by 2-way 956 
ANOVA with Tukey’s correction for multiple comparisons. 957 
 958 
Extended Data Figure 4. Response of high fat diet fed Gdf15 
-/-
 and Gfral
-/- 
mice 959 
to metformin. 960 
a, Circulating GDF15 levels   in high fat diet fed Gdf15 
+/+
 and Gdf15 
-/-
  mice given 961 
oral dose of metformin  ( 300mg/kg) once daily for 11 days. Data are mean ± SEM, 962 
mice as Figure 2a. All samples from Gdf15
-/-
 were below lower limit of assay (< 963 
2pg/ml), P value by 2-way ANOVA with Tukey’s correction for multiple comparisons. 964 
b,  Circulating GDF15 levels in high fat diet fed Gfral 
+/+
 and Gfral 
-/-
  mice  given oral 965 
dose of metformin  ( 300mg/kg) once daily for 11 days. Data are mean ± SEM, mice 966 
as Figure 2c, P by 2-way ANOVA with Tukey’s correction for multiple comparisons. 967 
c, Cumulative food intake in high fat diet fed Gfral 
+/+
 and Gfral 
-/- 
 mice on a high fat 968 
diet given oral dose of metformin  (300mg/kg) once daily for 11 days . Data are mean 969 
± SEM, mice as  Figure 2c, non-significant difference  vehicle vs metformin by 2W 970 
ANOVA. 971 
d, Fat mass ( left panel) and lean mass ( right panel)  in metformin-treated obese 972 
mice dosed with an anti-GFRAL antagonist antibody, weekly for 5 weeks, starting 4 973 
weeks after initial metformin exposure (mice as Figure 2d). Body composition was 974 
measured using MRI after 4 weeks of metformin exposure, prior to receiving anti-975 
GFRAL (week 4), after 6 weeks of metformin exposure and 2 weeks after receiving 976 
anti-GFRAL (week 6) and after 9 weeks of metformin exposure and 5 weeks after 977 
receiving anti-GFRAL (week 9). Data are mean ± SEM (n=7 Vehicle + control IgG 978 
and Metformin + anti – GFRAL; n=8 other groups); P by 2-way ANOVA with Tukey’s 979 
correction for multiple comparisons. 980 
 981 
Extended Data Figure 5. Response of second, independent cohort of high-fat 982 
diet fed Gdf15 
+/+
 and Gdf15 
-/-
 mice to metformin. 983 
a,b,c,   Percentage change in body weight (a),  absolute body weight (b)  and  984 
cumulative food intake (c)  in Gdf15 
+/+
 and Gdf15 
-/-
 mice on a high-fat diet treated 985 
with metformin (300mg/kg/day) for 11 days. Data are mean ± SEM (n=6/group, 986 
except Gdf15
 -/-
 vehicle= 7), P by 2-way ANOVA with Tukey’s correction for multiple 987 
comparisons. 988 
d, Circulating metformin levels in mice 6 hrs after final dose of metformin on day 11. 989 
Data are mean ± SEM (n=6/group, except Gdf15 
+/+
 vehicle= 4,   Gdf15 
-/-
 vehicle= 990 
7), P by 2-way ANOVA with Tukey’s correction for multiple comparisons. 991 
Extended Data Figure 6. Glucose, insulin  and GDF15 response to metformin. 992 
a, Fasting glucose from OGTT as Figure 3e and 3f. ANOVA analysis, effect of 993 
antibody p= 0.028, effect  of metformin p= 0.271, interaction of antibody and 994 
metformin p 0.707. 995 
b, Circulating GDF15 in mice undergoing ipGTT post single dose metformin as 996 
Figure 3 k and 3l. P by 2-way ANOVA with Tukey’s correction for multiple 997 
comparisons. 998 
c,d,  Fasting glucose (c)  and  fasting insulin (d)at time 0 of ipGTT as Figure 3 k and 999 
3l, non-significant by 2-way ANOVA. 1000 
e, AUC analysis of glucose levels as in Figure 3k and l. P by 2-way ANOVA, effect of 1001 
genotype p= 0.392, interaction of genotype and metformin p= 0.883. 1002 
f, Circulating GDF15 levels in high-fat diet fed Gdf15 +/+ mice after single oral dose 1003 
of metformin (600mg/kg). Samples were collected 6 hours after dosing, data are 1004 
mean ± SEM, (n=7/group), P value (95% confidence interval) by two tailed t-test. 1005 
 1006 
Extended Data Figure 7. a,  Representative images from the mouse with circulating  1007 
GDF15 level closest to group median shown in Fig4b with images from other regions 1008 
of the gut and from liver.  b,  In situ hybridization for Gdf15 mRNA expression (red 1009 
spots) in colon.  Tissue collected from  high-fat fed wild type mice, 6 hrs after single 1010 
dose of oral metformin (600mg/kg)( right side, red box, m1-m7) or vehicle gavage ( 1011 
left side, blue box, v1-v7),  n=7/group, mice as Figure 4. 1012 
Extended Data Figure 8. Analysis of Gdf15 mRNA expression (normalised to 1013 
expression levels of ActB) in tissue from high fat diet fed Gdf15 
+/+
 mice.   1014 
Metformin dose (300mg/kg) once daily for 11 days (see Figure 2a).  Data are mean 1015 
± SEM, n=6 metformin, n=7 vehicle, P value (95% confidence interval) by two tailed 1016 
t-test. 1017 
Extended Data Figure 9.Hepatic GDF15 response to biguanides. 1018 
a,b,Gdf15 mRNA expression in (a) primary mouse hepatocytes or (b) human iPSC 1019 
derived hepatocytes treated with vehicle control (Con) or metformin for 6 h. mRNA 1020 
expression is presented as fold expression relative to control treatment (set at 1), 1021 
normalised to Hprt and GAPDH gene in mouse and human cells,  respectively. Data 1022 
are expressed as mean ± SEM from four (a) and two (b) independent experiments. P 1023 
value (95% confidence interval)  by 1 way ANOVA  with Tukey’s correction for 1024 
multiple comparisons.  1025 
c,d, Circulating levels of GDF15 (c)  and  hepatic Gdf15 mRNA expression (d) 1026 
(normalised to2 microglobulin) in chow fed, wild type mice 4 hrs after single oral 1027 
dose of phenformin (300mg/kg). Data are mean ± SEM, n= 6/group,  P value (95% 1028 
confidence interval)   by  two tailed t-test.  1029 
e,  Representative image of  in situ hybridization for Gdf15 mRNA expression (red 1030 
spots) of fixed liver tissue derived from animals treated as described in (c) and (d). 1031 
Extended 10. Role of the Integrated Stress Response (ISR) in biguanide-1032 
induced Gdf15 expression 1033 
a,b, mRNA levels in kidney (a) and colon (b) isolated from obese mice 24 hours after 1034 
a single oral dose of metformin (600mg/kg). Data are mean ± SEM (n=5/group). P 1035 
values (95% confidence interval) by two tailed t-test.  Gdf15 mRNA fold induction 24 1036 
hrs post metformin 600mgs/kg is positively correlated with CHOP mRNA induction in 1037 
both kidney (a, right panel) and colon (b, right panel), black line= linear regression 1038 
analysis. 1039 
c-g,  Immunoblot analysis of ISR components (c) and  Gdf mRNA expression (d) in 1040 
wild type MEFs (mouse embryonic fibroblasts) treated with vehicle control (Con), 1041 
metformin (Met, 2 mM) or phenformin (Phen, 5 mM) or tunicamycin (Tn, 5 g/ml -1042 
used as a positive control) for 6 hrs. e, Gdf15 mRNA expression in ATF4 knockout 1043 
(KO) MEFs or (f) in control siRNA and CHOP siRNA transfected wild type MEFs 1044 
treated with Tn or Phen for 6 hrs or (g) in wild type MEFs pre-treated for 1 h either 1045 
with the PERK inhibitor GSK2606414 (GSK, 200 nM) or eIF2 inhibitor ISRIB (ISR, 1046 
100 nM) then co-treated with Phen for a further 6 hrs. mRNA expression is presented 1047 
as fold-expression relative to its respective control treatment (set at 1) or phen 1048 
treated samples (set as 100) with normalisation to Hprt gene expression. Data are 1049 
expressed as mean ± SEM from two for (c) and (d) and at least three independent 1050 
experiments for (e-g).  P value (95% confidence interval) by two tailed t-test relative 1051 
to Phen treated control wild and control siRNA treated samples. 1052 
h, GDF15 protein in supernatant of mouse derived 2D duodenal organoids treated 1053 
with metformin in the absence or presence of ISRIB (1 M). Data are expressed as 1054 
mean ± SEM from two independent experiments. From each well, measurement of 1055 
protein was at least in duplicate. P by 2 way ANOVA with Sidak’s correction for 1056 
multiple comparisons. 1057 
i, GDF15 protein in supernatants of mouse-derived 2D duodenal organoids from wild 1058 
type and CHOP null mice treated with metformin from two independent experiments 1059 
From each well, measurement of  protein was at least in duplicate. Data are mean ± 1060 
SEM, P value (95% confidence interval)  by two-tailed t-test. 1061 
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